Amets Biotechnology is a biotechnology company founded in 2025 dedicated to developing innovative gene therapies for rare pediatric diseases, created with the commitment to offer curative options to children facing severe conditions with no effective therapeutic alternatives.
Its purpose goes beyond scientific advancement: it seeks to generate meaningful social impact by transforming the prognosis and quality of life of pediatric patients and their families. Built on a strong scientific foundation and led by a team internationally recognized for its leadership in gene therapy, the company combines technological excellence, strategic vision, and translational expertise to accelerate the delivery of innovative therapeutic approaches into the clinical setting.
Its work focuses on designing high-precision therapeutic solutions, leveraging advanced platforms and specialized knowledge to maximize the safety, efficacy, and feasibility of its developments. Amets directs its efforts toward rigorous preclinical validation and clinical trial readiness, building a robust pipeline aimed at reshaping the therapeutic paradigm for rare pediatric diseases.
The combination of scientific innovation, global outlook, and social commitment positions the company as an emerging reference in advanced therapies, dedicated to bringing hope and real solutions to those who need them most.
